Ikena slashes workforce, cuts back discovery work to focus on lead oncology assets

2024-01-19

临床1期蛋白降解靶向嵌合体

Ikena Oncology plans to reduce its workforce by approximately 35% as it focuses efforts on its two clinical-stage cancer drugs.

The company noted that the downsizing will see it reallocate resources from exploratory research and discovery towards advancing development of the lead assets IK-930 and IK-595. CEO Mark Manfredi said Ikena expects “interpretable and clear data reads” for the two candidates this year.

In November, Ikena’s shares sunk 69% after initial data from the dose-escalation part of IK-930’s Phase I study in patients with mesothelioma and epithelioid hemangioendothelioma highlighted proteinuria as an adverse effect of special interest. The company said that an optimised formulation of the TEAD1-selective Hippo pathway inhibitor is now being investigated alongside the original formulation, with an update expected in the latter part of 2024.

Meanwhile, dose escalation is ongoing in a study of IK-595, a MEK-RAF molecular glue, with the programme continuing to enrol patients with RAS and RAF mutations.

Ikena had around $175 million in cash and equivalents as of December 31, which is now expected to fund operations into the first half of 2026.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构